NASDAQ$IMCR

Immunocore Holdings plc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Headline financials

Total Revenue

$55.1M

Previous: $29.6M+86.4%
EPS (adj)

-$0.43

Previous: -$0.48+10.4%
KIMMTRAK Net Sales

$51.6M

No prior period
R&D Expenses

$36.6M

No prior period
SG&A Expenses

$32.6M

No prior period
Capital Expenditures

$3M

No prior period
Free Cash Flow

$7.54M

No prior period
Net Income

-$17.8M

No prior period
Operating Income

-$20M

No prior period
Gross Profit

$59.4M

No prior period
Cash & Equivalents

$418M

No prior period
Stock-Based Comp

$8.26M

No prior period

Revenue & EPS history

Immunocore · Revenue · Quarterly

$55.1M

Q1 2023+86.4%vs Q1 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-0.3%

Avg return

Earnings day

+0.9%

Avg return

5 days after

-1.2%

Avg return

30 days after

48%

10 / 21 earnings

Positive

+8.3%

Q3 2023

Best reaction

-11.0%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.6%+0.0%-2.1%
Q4 2025-4.8%-3.0%-12.6%
Q3 2025-3.2%+9.7%+21.5%
Q1 2025+6.3%+5.3%+32.8%
Q4 2024+5.3%-1.1%+1.3%
Q3 2024+4.0%+5.0%-4.5%
Q2 2024+0.8%+1.7%-9.5%
Q1 2024-1.9%-6.6%-31.7%
Q4 2023-4.6%-7.2%-7.7%
Q3 2023+8.3%+4.6%+15.8%
Q2 2023-3.3%-5.9%-12.7%
Q1 2023-1.5%+3.2%-4.6%
Q4 2022-4.9%-5.1%-9.9%
Q3 2022+2.9%+13.7%+9.3%
Q2 2022+1.6%+5.8%-13.5%
Q1 2022-11.0%+2.7%+1.4%
Q4 2021-0.7%+7.5%+37.7%
Q3 2021+0.4%-0.2%-21.3%
Q2 2021-4.9%-9.5%-1.4%
Q1 2021-1.5%-9.4%-5.3%
Q4 2020+0.1%+6.8%-7.1%
Q3 2020
Q2 2020
Q1 2020
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro